Athimalaipet V Ramanan
Bristol Royal Hospital for Children
291 Papers
1K Citations
Athimalaipet V Ramanan is an academic researcher from Bristol Royal Hospital for Children. The author has contributed to research in topics: Medicine & Uveitis. The author has an hindex of 44, co-authored 236 publications. Previous affiliations of Athimalaipet V Ramanan include University of Toronto & Royal National Hospital for Rheumatic Diseases.
Chat about Author
Papers
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Paul La Rosée,AnnaCarin Horne,Melissa Hines,Tatiana von Bahr Greenwood,Rafał Machowicz,Nancy Berliner,Sebastian Birndt,Juana Gil-Herrera,Michael Girschikofsky,Michael B. Jordan,Ashok Kumar,Jan A M van Laar,Gunnar Lachmann,Kim E. Nichols,Athimalaipet V Ramanan,Yini Wang,Zhao Wang,Gritta Janka,Jan-Inge Henter +18 more
TL;DR: In this article, the authors present expert opinions derived from an interdisciplinary working group on adult HLH, sponsored by the Histiocyte Society, to facilitate knowledge transfer between physicians caring for pediatric and adult patients with HLH with the aim to improve the outcome for adult patients affected by HLH.
823
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative
Angelo Ravelli,Francesca Minoia,Sergio Davì,AnnaCarin Horne,Francesca Bovis,Angela Pistorio,Maurizio Aricò,Tadej Avcin,Edward M. Behrens,Fabrizio De Benedetti,Lisa Filipovic,Alexei A. Grom,Jan-Inge Henter,Norman T. Ilowite,Michael B. Jordan,Raju Khubchandani,Toshiyuki Kitoh,Kai Lehmberg,Daniel J. Lovell,Paivi Miettunen,Kim E. Nichols,Seza Ozen,Jana Pachlopnik Schmid,Athimalaipet V Ramanan,Ricardo Russo,Rayfel Schneider,Gary Sterba,Yosef Uziel,Carol A. Wallace,Carine Wouters,Nico M Wulffraat,Erkan Demirkaya,Hermine I. Brunner,Alberto Martini,Nicolino Ruperto,Randy Q. Cron +35 more
TL;DR: Criteria for the classification of macrophage activation syndrome (MAS) in patients with systemic juvenile idiopathic arthritis (JIA) is developed.
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
Manu Shankar-Hari,Claire L Vale,Peter J. Godolphin,David Fisher,Higgins Jpt.,Francesca Spiga,Jelena Savović,Jelena Savović,Jayne F. Tierney,Gabriel Baron,Julie Benbenishty,Lindsay R. Berry,N Broman,Alexandre Biasi Cavalcanti,R Colman,S. De Buyser,Derde Lpg.,P Domingo,S F Omar,A Fernandez-Cruz,T Feuth,F Garcia,R Garcia-Vicuna,I Gonzalez-Alvaro,Anthony C. Gordon,Richard Haynes,Olivier Hermine,Peter Horby,Nora Horick,K Kumar,B N Lambrecht,Martin J Landray,L Leal,D J Lederer,Elizabeth Lorenzi,X Mariette,N Merchante,N A Misnan,S V Mohan,M C Nivens,J Oksi,J A Perez-Molina,R Pizov,R Porcher,S Postma,R Rajasuriar,Athimalaipet V Ramanan,P Ravaud,Pankti Reid,Abraham Rutgers,A Sancho-Lopez,Todd B. Seto,S Sivapalasingam,A S Soin,Natalie Staplin,John H. Stone,Garth W. Strohbehn,J Sunden-Cullberg,J Torre-Cisneros,L W Tsai,H. van Hoogstraten,T. van Meerten,Viviane C Veiga,P E Westerweel,Srinivas Murthy,Janet V. Diaz,John C. Marshall,Sterne Jac. +67 more
TL;DR: In this article, a prospective meta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Vincent C. Marconi,Vincent C. Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E. Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B. Piruzeli,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda J. Crowe,Paulo Reis,Xin Zhang,David H. Adams,E. Wesley Ely +19 more
TL;DR: Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties as discussed by the authors, which has been shown to reduce mortality in hospitalised adults with COVID-19.
435
Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies.
TL;DR: Systematic review and meta-analysis of observational studies published between 1966 and June 2004 showed that breast feeding during the introduction of dietary gluten, and increasing duration of breast feeding were associated with reduced risk of developing CD.
376